Download or read book Harm Reduction Evidence Impacts and Challenges written by Tim Rhodes (Medical sociologist) and published by . This book was released on 2010 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The EMCDDA's 10th scientific monograph, entitled Harm reduction: evidence, impacts and challenges provides a comprehensive overview of the harm reduction field. Part I of the monograph looks back at the emergence of harm reduction approaches and their diffusion, and explores the concept from different perspectives, including international organisations, academic researchers and drug users. Part II is dedicated to current evidence and impacts of harm reduction and illustrates how the concept has broadened to cover a wide range of behaviours and harms. Part III addresses the current challenges and innovations in the field. The core audience of the monograph comprises policymakers, healthcare professionals working with drug users, as well as the wider interested public -- EU Bookshop.
Download or read book Registries for Evaluating Patient Outcomes written by Agency for Healthcare Research and Quality/AHRQ and published by Government Printing Office. This book was released on 2014-04-01 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
Download or read book European Drug Prevention Quality Standards written by and published by . This book was released on 2011 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Pain Management and the Opioid Epidemic written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2017-09-28 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Download or read book World Drug Report 2007 written by United Nations Office on Drugs and Crime and published by United Nations. This book was released on 2007-06-27 with total page 282 pages. Available in PDF, EPUB and Kindle. Book excerpt: This report offers one of the most comprehensive insights into global trends in international culture, production, seizure and price of illicit drugs. It examines trends in the world's four major markets: opium and heroin, coca and cocaine, cannabis, and amphetamine-type stimulants. This edition provides an in-depth examination of the link between transnational organized crime and drug trafficking. A detailed statistical appendix on production, prices and consumption completes this book, which gives the reader a comprehensive picture of the world's drug problem.
Download or read book Novel Psychoactive Substances written by Ornella Corazza and published by Springer. This book was released on 2017-08-09 with total page 192 pages. Available in PDF, EPUB and Kindle. Book excerpt: In light of the recent emergence of Novel Psychoactive Substances (NPS) on a global scale, this book provides a timely analysis of the social and economic impact of the NPS phenomenon, and of the global policy and regulatory responses to it. It presents the first comprehensive overview of the international regulation, policy and market structure of the NPS phenomenon, offering a guide to inform legislative discussions and demonstrating from a comparative perspective the different approaches used to address the rise of NPS to date. It covers topics such as organized crime, drug markets, clinical evidence on NPS, and different regulatory approaches also in less explored settings such as prisons and sport environments. Overall, this highly informative and well-structured repository of different experiences with NPS policy, law and regulation offers an essential primary source of evidence for anyone interested in the area of drug and NPS policy, health economics and p ublic health.
Download or read book Sharing Clinical Trial Data written by Institute of Medicine and published by National Academies Press. This book was released on 2015-04-20 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.
Download or read book Fulltext Sources Online written by and published by . This book was released on 2007 with total page 1666 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Governance of Addictions written by Tamyko Ysa and published by OUP Oxford. This book was released on 2014-05-15 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: Why is governance of addiction so difficult? What can we learn from recent experiences and efforts in Europe? Governance of Addictions analyses the multidisciplinary research which has been used as a framework for understanding how governments formulate and implement addiction policies in 27 European Union member states plus Norway, looking in detail at four substances: heroin, cannabis, alcohol and tobacco. Presenting the methodological design for the study research, this book comprehensively analysing international trends, with a special focus on the role of the EU and its governance of addictions modes, this volume sheds light on the current situation of the governance of addictive substances and behaviours and facilitate new approaches to dealing with addiction. Based on the research from ALICE RAP (Addiction and Lifestyles in Contemporary Europe, Reframing Addictions Project), a unique project studying the place of addictive substances and behaviours in contemporary European society, Governance of Addictions is essential reading for policy-makers, public managers, practitioner and stakeholders influencing policy for addictive substances and behaviours, as well as academics and public health professionals.
Download or read book Medical Devices and the Public s Health written by Institute of Medicine and published by National Academies Press. This book was released on 2011-11-25 with total page 318 pages. Available in PDF, EPUB and Kindle. Book excerpt: Medical devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the FDA 510(k) process. In recent years, individuals and organizations have expressed concern that the 510(k) process is neither making safe and effective devices available to patients nor promoting innovation in the medical-device industry. Several high-profile mass-media reports and consumer-protection groups have profiled recognized or potential problems with medical devices cleared through the 510(k) clearance process. The medical-device industry and some patients have asserted that the process has become too burdensome and is delaying or stalling the entry of important new medical devices to the market. At the request of the FDA, the Institute of Medicine (IOM) examined the 510(k) process. Medical Devices and the Public's Health examines the current 510(k) clearance process and whether it optimally protects patients and promotes innovation in support of public health. It also identifies legislative, regulatory, or administrative changes that will achieve the goals of the 510(k) clearance process. Medical Devices and the Public's Health recommends that the U.S. Food and Drug Administration gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices. According to the report, the FDA's finite resources are best invested in developing an integrated premarket and postmarket regulatory framework.
Download or read book EU Lobbying Empirical and Theoretical Studies written by David Coen and published by Routledge. This book was released on 2013-10-31 with total page 173 pages. Available in PDF, EPUB and Kindle. Book excerpt: EU Lobbying: Empirical and Theoretical studies offers an analysis of large empirical studies of interest group politics and Lobbying in Europe. Recognising the continued European economic integration, globalisation and the changing role of the state, it observs significant adaptations in interest mobilisation and strategic behavour. This book assesses the logic of collective and direct action, the logic of access and influence, the logic of venue-shopping and alliance building. It addresses specific issues such as: the emergence of elite pluralism in EU institutions, the pump priming of political action by EU institutions, and the growing political sophistication of private and public interests in Brussels. Through these issues the book explores how interest groups lobby different European institutions along the policy process and how the nature of policy dictates the style and level of lobbying. This book was previously published as a special issue of Jounal of European Public Policy
Download or read book Improving Healthcare Quality in Europe Characteristics Effectiveness and Implementation of Different Strategies written by OECD and published by OECD Publishing. This book was released on 2019-10-17 with total page 447 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume, developed by the Observatory together with OECD, provides an overall conceptual framework for understanding and applying strategies aimed at improving quality of care. Crucially, it summarizes available evidence on different quality strategies and provides recommendations for their implementation. This book is intended to help policy-makers to understand concepts of quality and to support them to evaluate single strategies and combinations of strategies.
Download or read book Making Medicines Affordable written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2018-03-01 with total page 235 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Download or read book European Drug Report written by Observatoire européen des drogues et des toxicomanies and published by . This book was released on 2020 with total page 83 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book World Drug Report 2020 written by United Nations and published by . This book was released on 2021-01-06 with total page 420 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drawing on the Household Living Arrangements of Older Persons 2019 Dataset, the World Population Ageing 2020 Highlights will document key patterns and trends of the household living arrangements of older persons around the world.
Download or read book Cannabis written by Michał Wanke and published by Taylor & Francis. This book was released on 2024-06-14 with total page 137 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book demonstrates how culture matters for the understanding of cannabis use. It stems from the growing body of research on how users manoeuvre stigmatisation and celebrate the subcultural status of cannabis amid rapid transformation of the substance and its societal reception. The volume presents international studies that challenge the normalisation thesis and simplified views on patterns of use, as well as the Western bias in social research of cannabis. Chapters in this book map the variability of cannabis cultures and markets on a global scale including digital, regulated and illicit markets in transformation. They study cannabis through stigmatisation, gender, social worlds, symbolic boundaries, subcultures, and identity work. The chapters address diverse themes, such as how Latvian, Polish, Nigerian or Mexican users negotiate mainstream conservative, and sometimes gendered societal reactions to cannabis - and how Nordic users’ identities are played out in more progressive contexts. Chapters also cover cannabis use by older people and small growers’ cultures in the US and the interconnections between the established cultures and their digital augmentation in Australia. Synthetic cannabis use is studied in New Zealand and the many contradictions of contemporary cannabis policies are highlighted throughout. Taken together, this book offers an assortment of studies that provide a descriptive and conceptual snapshot of ongoing transitions of paradoxically stable cannabis cultures. It was originally published as a special issue of Drugs: Education, Prevention and Policy.
Download or read book Cannabis Legislation in Europe written by Brendan Hughes and published by . This book was released on 2018 with total page 30 pages. Available in PDF, EPUB and Kindle. Book excerpt: "At a time of increased debate on the laws controlling the use of cannabis in the European Union, this report answers some of the questions most often asked about cannabis legislation. Using a question and answer format, basic definitions and the obligations of countries under international law are set out in a section on ‘What is cannabis and what are countries’ obligations to control it?‘ Two following sections examine the links and disparities between the content of the laws and their guidelines on the one hand and the actual implementation of the laws on the other. The final question and answer section considers whether changes in law have affected cannabis use and how much public support for legal change exists, as it looks at the future direction of cannabis legislation in Europe." -- Provided by publisher.
